Extreme Vision has called a virtual extraordinary general meeting (EGM) for 11:00 a.m. on 16 October 2026 to seek shareholder approval for three special resolutions that could reshape its capital structure and support subsidiary growth.
Key proposals 1. Articles of Association update • Management is requesting shareholder consent to amend the Articles of Association to reflect the conversion of 562,347 unlisted domestic shares into H shares under the company’s full-circulation plan. • The revised Articles will take effect upon completion of the conversion and subsequent regulatory filings.
2. Revocation and renewal of share-issue mandate • The current general mandate, granted at the June 2026 AGM and still unused, will be revoked. • A fresh mandate will empower the Board to issue new shares (including any sale or transfer of treasury shares) or convertible securities of up to 20 % of the issued share capital (excluding treasury shares) as at the approval date. • The mandate will remain valid until the next AGM or its revocation by shareholders, whichever occurs first.
3. Capital injection into Hengqin Extreme Vision • The company plans to inject RMB138.00 million into wholly-owned subsidiary Zhuhai Hengqin Extreme Vision Technology Co., Ltd. • Post-transaction, Extreme Vision will retain 100 % ownership. The funding will be sourced from internal resources to enhance the subsidiary’s capital base and market competitiveness. • The injection does not constitute a notifiable or connected transaction under Chapters 14 and 14A of the Hong Kong Listing Rules.
Administrative details • The EGM will be conducted online via the Vistra eVoting Portal; shareholders may vote electronically or by proxy. • The share register will close from 13 to 16 October 2026; transfers must be lodged by 4:30 p.m. on 12 October 2026 to qualify for attendance and voting. • All EGM resolutions will be decided by poll, and results will be published on the HKEX and company websites.
Management views The Board states that the refreshed mandate offers flexibility for timely capital raising, while the subsidiary capital injection aims to fortify long-term growth. Directors affirm that the proposals align with shareholder interests and recommend voting in favour at the forthcoming EGM.
Comments